Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Osner Etienne

Nurse Practitioner, Psychiatric/Mental Health Hollywood, FL Nurse Practitioner

NPI 1942807367 CMS profile 10820184

7369 Sheridan St Ste 101, Hollywood, FL 33024

Open in the dashboard

General payments

$16,497

797 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Osner Etienne of Hollywood, FL is reported in the CMS Open Payments database as having received $16,497 across 797 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,758 231
2024 General $3,824 175
2023 General $3,859 182
2022 General $2,537 129
2021 General $1,520 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Osner Etienne
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Osner Etienne were reported at $4,758. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Osner Etienne Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,520 $166 $54–$482 $132
2022 $2,537 $195 $66–$559 $149
2023 $3,859 $233 $82–$673 $160
2024 $3,824 $236 $84–$688 $164
2025 $4,758 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ITI, Inc. $1,534 73 payments
  2. Neurocrine Biosciences, Inc. $1,435 48 payments
  3. AbbVie, Inc. $1,432 79 payments
  4. Alkermes, Inc. $1,316 65 payments
  5. Teva Pharmaceuticals USA, Inc. $1,302 91 payments
  6. Otsuka America Pharmaceutical, Inc. $1,285 57 payments
  7. Axsome Therapeutics, Inc. $962 37 payments
  8. Indivior Inc. $936 42 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $872 41 payments
  10. Almatica Pharma LLC $822 42 payments
  11. Other $4,603 222 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,497 797 payments
Products named General payments · program years 2021–2025
  1. INGREZZA $1,435 48 payments
  2. ARISTADA Cns $1,209 58 payments
  3. ARISTADA Cns $1,209 58 payments
  4. VRAYLAR $1,115 61 payments
  5. LYBALVI $1,112 55 payments
  6. REXULTI $1,078 46 payments
  7. CAPLYTA $1,007 44 payments
  8. Auvelity $962 37 payments
  9. ARISTADA Cns $956 45 payments
  10. ARISTADA Cns $956 45 payments
  11. Other $12,210 626 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

3,189

Median for Nurse Practitioner: 389

Drug cost

$270,871

Median for Nurse Practitioner: $21,885

Branded share of claims

17.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 17 $136,469
Invega Sustenna Paliperidone Palmitate Brand 13 $31,811
Vraylar Cariprazine Hcl Brand 12 $16,736
Rexulti Brexpiprazole Brand 11 $16,538
Xanax Alprazolam Brand 12 $10,607
Nuedexta Dextromethorphan Hbr/Quinidine Brand 11 $8,315
Adzenys Xr-Odt Amphetamine Brand 12 $5,995
Quviviq Daridorexant Hcl Brand 11 $5,472
Loreev Xr Lorazepam Brand 11 $4,198
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 29 $3,750

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$9,730

Medicare's payments for the services billed

Medicare patients

26

Average age 64

Services billed

154

13 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Depression 65%
Arthritis 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
$544 11 —
INGREZZA
$437 17 —
CAPLYTA
$432 — —
Auvelity
$281 — —
Austedo XR
$267 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

797 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record